These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Killackey MA; Davis AR Gynecol Oncol; 1993 Nov; 51(2):171-4. PubMed ID: 8276289 [TBL] [Abstract][Full Text] [Related]
3. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Silva EG; Tornos CS; Malpica A; Gershenson DM Mod Pathol; 1997 Jul; 10(7):663-7. PubMed ID: 9237175 [TBL] [Abstract][Full Text] [Related]
4. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Le T; Alshaikh G; Hopkins L; Faught W; Fung MF Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146 [TBL] [Abstract][Full Text] [Related]
6. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307 [TBL] [Abstract][Full Text] [Related]
7. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A; Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209 [TBL] [Abstract][Full Text] [Related]
8. [Treatment and prognostic factors for stage IV epithelial ovarian cancer]. Wu M; Shen K; Lang J Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158 [TBL] [Abstract][Full Text] [Related]
9. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784 [TBL] [Abstract][Full Text] [Related]
10. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. Earle CC; Schrag D; Neville BA; Yabroff KR; Topor M; Fahey A; Trimble EL; Bodurka DC; Bristow RE; Carney M; Warren JL J Natl Cancer Inst; 2006 Feb; 98(3):172-80. PubMed ID: 16449677 [TBL] [Abstract][Full Text] [Related]
11. Uterine papillary serous carcinoma: patterns of failure and survival. Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700 [TBL] [Abstract][Full Text] [Related]
12. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
13. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors). Seidman JD; Kurman RJ Cancer; 2002 Aug; 95(4):675-6. PubMed ID: 12209708 [No Abstract] [Full Text] [Related]
15. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406 [TBL] [Abstract][Full Text] [Related]
16. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644 [TBL] [Abstract][Full Text] [Related]
17. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030 [TBL] [Abstract][Full Text] [Related]
18. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825 [TBL] [Abstract][Full Text] [Related]
19. [Normal-sized ovary carcinoma syndrome--clinical and pathological analysis of 11 cases]. Yao Z; Li L; Yang H Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):383-6. PubMed ID: 10921039 [TBL] [Abstract][Full Text] [Related]
20. Study of ovarian cancer management. Gaughan E; Javaid T; Cooley S; Byrne P; Gaughan G Ir Med J; 2006 Oct; 99(9):279-80. PubMed ID: 17144239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]